07/09/2020

Gianmarco Negrisoli talks Flamma with TKS

As part of their Wednesday Chats, TKS Publishing i...

MORE

Gianmarco Negrisoli talks Flamma with TKS

07/09/2020

As part of their Wednesday Chats, TKS Publishing interviewed Gianmarco Negrisoli, President of Flamma USA, on July 8, 2020. This short video interview gives one a glimpse of what Flamma is all about. If you have about ten minutes, it is worth your time.

Gianmarco Negrisoli talks Flamma

06/19/2020

FLAMMA FRIDAYS begin June 26- meet virtually, anonymously & learn about Flamma

Chignolo D’Isola, Bergamo, Italy – June 19, 2020 –...

MORE

FLAMMA FRIDAYS begin June 26- meet virtually, anonymously & learn about Flamma

06/19/2020

Chignolo D’Isola, Bergamo, Italy – June 19, 2020 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, will bring forth a novel way to learn about Flamma and their offerings. Beginning June 26th, Flamma will host a series of 15 minute informational meetings online every 4th Friday of the month.

There will be no need to register or sign in since the online experience will take place in a virtual meeting room. This allows people to take advantage of the technology available to us yet remain anonymous. Flamma values your privacy and does not feel it is useful to have one sign up with their full contact information to learn about Flamma’s offerings.

This series of virtual meetings will allow those located in varying time zones to selected what time works for them. There will be three separate meetings held on the following Fridays: June 26, July 24, August 28, September 25 and October 23 at the following times:

9:00AM ET/15:00 CET (morning on the East Coast, afternoon in Europe)

8:00AM PT/11:00AM ET/17:00 CET (morning on the West Coast, evening in Europe)

11:00AM PT/2:00PM ET (late morning on the West Coast, afternoon on the East Coast)

Join anonymously using the following link: https://pexip.me/meet/0148100399

During these challenging times, there are still pharmaceutical projects that need to move forward thus finding the right outsourcing partner is critical. Flamma wants to provide sourcing professionals, CMC team leaders, executives from large and small companies and anyone else (including competitors) the opportunity to expand their CDMO portfolio.

05/21/2020

FLAMMA breaks ground for new R&D building in Italy

Chignolo D’Isola, Bergamo, Italy – May 21, 20209 –...

MORE

FLAMMA breaks ground for new R&D building in Italy

05/21/2020

Chignolo D’Isola, Bergamo, Italy – May 21, 20209 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce the ground breaking for their new R&D building. While most CEOs use a gold plated shovel, Flamma’s CEO Gian Paolo Negrisoli, used an excavator to mark the groundbreaking of the new R&D Building at Flamma’s headquarters in Chignolo d’Isola, Bergamo, Italy.

This marks the expansion at Flamma’s headquarters that will allow Flamma to quadruple its R&D space. The R&D building will accommodate 50 additional employees providing additional R&D and analytical development laboratories as well as offices and meeting rooms. In addition to these features, there will be a lab for high containment and special chemistries.

During the Covid-19 crisis of 2020, our teams in Italy and China worked tirelessly to continue production of important molecules that are critical to help fight the virus. The Italian team hung a sign reading #MOLAMIA which means ‘Don’t Give Up’. Flamma doesn’t give up. This important milestone is another example of the commitment made to not only customers but employees to deliver a first class organization where people want to place their projects.

The new R&D building will serve as a complement the R&D work being done at Flamma USA in Malvern, PA outside of Philadelphia. The team in the USA continues to grow as more projects come on board. For further information, please visit the Flamma website at http://www.flammagroup.com.

View a one minute video here: https://vimeo.com/424568102

04/16/2020

Flamma named Best Global Pharmaceutical CDMO

Chignolo D’Isola, Bergamo, Italy – April 16, 2020 ...

MORE

Flamma named Best Global Pharmaceutical CDMO

04/16/2020

Chignolo D’Isola, Bergamo, Italy – April 16, 2020 – Flamma has been named the Best Global Pharmaceutical CDMO according to the 2020 Biotechnology Awards.

Read more at: https://www.ghp-news.com/issues/biotechnology-awards-2020/

Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, would like to thank the 2020 Biotechnology Awards for their selection of Flamma. This is a testament to the entire Flamma team.

The Flamma team is pictured above at our headquarters in Chignolo d’Isola, Italy

07/02/2020

Flamma named Top 10 CMO in Europe

Chignolo D’Isola, Bergamo, Italy – April 6, 20209 ...

MORE

Flamma named Top 10 CMO in Europe

04/06/2020

Chignolo D’Isola, Bergamo, Italy – April 6, 20209 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that Flamma has been named a Top 10 CMO in Europe by Pharma Tech Outlook. Read more at:

https://cmo-europe.pharmatechoutlook.com/vendor/flamma-group-spearheading-the-pharma-supply-chain-cid-681-mid-64.html

Flamma named Top 10 CDMO in Europe

06/13/2020

FLAMMA : Covid-19 outbreak and impact to Flamma Italy

March 11, 2020 Re: Covid-19 outbreak and impact to...

MORE

FLAMMA : Covid-19 outbreak and impact to Flamma Italy

03/12/2020

March 11, 2020

Re: Covid-19 outbreak and impact to Flamma Italy

Dear Partners and Friends,

I would like to reach out and provide you with a better picture of what the situation looks like in Italy and at Flamma. As you are reading in the newspapers, the situation in Italy is worsening every day: infections are growing exponentially and we don’t know when the peak will hit. The majority of the people infected manifest light symptoms and can be cured at home but many still need hospitalization and, a few, but still too many, are critical and need Intensive Care Units, unfortunately for weeks and not for days.

As Italian, I’m very proud of our Healthcare system but with these numbers even the best system will collapse and we are very close to this point. When my friends at hospital say that they’ll need soon to select which patients can be admitted and which not, you can understand that we reacted too little and too late.

As many others, I underestimated the danger. I thought that doctors words were exaggerated and with few precautions, we would have been safe from Covid19. Now, I can say that it was a big mistake because infections are still growing and the latest measures taken by the government were extremely necessary to stop the infection growth. Unfortunately the impact on our activity is extremely significant.

Flamma, till now, worked at full stream despite the emergency as well as the seasonal flu which typically reduces the workforce. We are now compelled to slow down the production from next week because the transportation of raw materials, mainly solvents, will worsen and because we are facing a progressive reduction of our workforce.

As of today no employee has tested positive for the virus. We took important measures to prevent infections inside the company. These include: 20% of our employees are currently working remotely from home; we have completely segregated teams on shifts in Production, QC, and RD, limiting contacts between these teams; we are doing sanitization between shifts in the changing room; enforcing strict rules for accessing to the cafeteria and break areas and reviewing procedures to work at distance; we manufactured large volumes of liquid sanitizer because it’s not available in the market , like masks : we are now buying them from china after having sent thousands to Honkai last month. Situation in China has significantly improved, thanks to the very strong measures implemented. Flamma Honkai now works at full stream and is delivering without issues by air and, with some delays, by sea.

I’m writing you this letter asking you to not underestimate the Coronavirus issue. The curve of infections in other countries is already similar to what we had in Italy some days ago and, I suppose, in the USA it will likely happen with a one or two week delay. Please take immediate decisions that we took too late and follow the most basic rules by especially limiting exposure to public areas.

At Flamma, we feel we are on the front line to deliver treatment to patients who need it now more the ever. We plan to continue our activity until we are able to guarantee the health and safety of our people. There will be for sure some delays but I want to assure you that the entire Flamma team is highly committed in delivering what is most needed now. It will be our duty to inform you immediately if the situation changes in the next few days.

I want to thank you for your support in this difficult time and for your trust in Flamma as a partner.

Sincerely,

Gian Paolo Negrisoli

President and CEO

05/27/2020

FLAMMA CEO given Chinese Citizenship for business efforts in China

Chignolo D’Isola, Bergamo, Italy – November 21, 20...

MORE

FLAMMA CEO given Chinese Citizenship for business efforts in China

11/22/2019

Chignolo D’Isola, Bergamo, Italy – November 21, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that Mr. Gian Paolo Negrisoli,  Flamma CEO, has been granted Honorary Dalian Citizenship for his friendship to China and his contribution in promoting economic exchanges and cooperation through Flamma Honkai. Negrisoli is the first Italian to receive such Award, the 145th in city history. Dalian, located in the Liaoning Province, has the largest multi-purpose port in Northeast China and has a population over 7 million people.

Part of the Flamma Group from 2011, Flamma Honkai is a 100% owned and managed facility. Flamma Honkai is part of the fully integrated supply chain (combining Italy, China, and the USA) that Flamma offers its customers.

Flamma Honkai, located in Songmudao Chemical Park, opened its new cGMP workshop, new R&D labs and new QC labs in June 2017. Flamma Honkai will begin construction of a state of the art facility on a new site in 2020 as it continues to be one of most reliable and qualified CDMOs in Asia.

Contact Flamma

Kenneth Drew, Ph.D., Sr. Director, North America Sales and Business Development

1-617-515-0975

04/16/2020

Flamma participates in the VIPCAT project

The VIPCAT project aims to develop new approaches,...

MORE

Flamma participates in the VIPCAT project

09/30/2019

The VIPCAT project aims to develop new approaches, through chemical and enzymatic synthesis, for the preparation of aroma and fragrances and active pharmaceutical ingredients (APIs), with high atom economy and green process.

Flamma implements this technology and know-how on its Generic APIs, using Continuous flow chemistry and Solid state techniques through a collaboration with the partnership VIPCAT. This will help to extend its influence in the field of aroma and fragrance synthesis as well as for new synthetic resins for enzyme immobilization.

07/01/2019

FLAMMA acquires Teva’s Philadelphia cGMP facility marking entry into the US marketplace with labs & pilot plant

Chignolo D’Isola, Bergamo, Italy – July 1, 2019 – ...

MORE

FLAMMA acquires Teva’s Philadelphia cGMP facility marking entry into the US marketplace with labs & pilot plant

07/01/2019

Chignolo D’Isola, Bergamo, Italy – July 1, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that the company has acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area.

“The industry knows and respects the Flamma brand, yet some customers are apprehensive when considering the placement of a project overseas. Flamma understands this and feels that this will be a good option for those wanting to initially start a project close to home,” said Kenneth Drew, Ph.D., Sr. Director of North America Sales and Business Development.

“This facility will be a welcome addition to Flamma’s current customer base as well. Having a US cGMP facility provides further flexibility and options to customers as Flamma continues to grow its R&D teams. Using our unique model of Flamma Academy, we will be able to have R&D chemists from both Italy and China to spend time in the Philly area labs and understand what customers want a first hand. It also helps to bring the entire company together by pairing Italian, Chinese and American scientists together. Flamma is the Thinking CDMO.”

GianMarco Negrisoli, President of Flamma Innovation (the R&D unit within the Flamma Group), noted, “This is another example of the strategic vision for Flamma. The goal is to be recognized by customers as a strategic partner that is ready to invest when and where customers need us to.”

40,000 sq. ft. the facility is in close proximity to Boston/Cambridge (1.5 h flight) as well as the greater New York/New Jersey area (1.5 h drive). Affectionately being dubbed “Flamma-delphia” for now, this extremely well built lab and manufacturing site possesses  a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 6 standard cGMP kilo lab suites, 1 cGMP HPAPI kilo lab suite with isolators that have been classified 3b (Roche) or band 4 (Safebridge), 22 fume hoods, an analytical development lab as well as a QC lab, and additional space for future expansion for any necessary analytical, chemistry, and/or  warehouse needs. Also, the site previously handled controlled drug substances (Schedule II to IV) and Flamma looks forward to reactivating the necessary licenses.

This site will be to be initially dedicated to the development and, production of APIs ranging from pre-clinical/clinical (Phases 1 to 3) and up to commercial phase (after future FDA inspection) with the scale being dependent on the forecasted quantities. Flamma plans to grow the site to 60 employees by 2023 and looks forward to attracting talented personnel

As part of the growing demands of the industry, Flamma has carefully examined various options over the past few years for growth. Flamma felt it was best to start a laboratory operation from the ground floor than try to incorporate an already existing business. By doing this, Flamma can continue to impart its unique culture to its employees from day one and bring value to customers knowing that the same family owned and run culture permeates the new site. This site will be able to quickly accommodate fast-tracked molecules and respond to the constantly growing analytical needs of today’s projects.

This milestone complements the Flamma 2020 Plan to bring value to customers who are looking for a home for their projects and have numerous options to move it forward at the right time. These options include moving projects later on to Flamma’s cGMP facilities in Italy, its cGMP facility in Dalian, China, or taking advantage of both by back integrating the project appropriately. 

This acquisition comes on the heels of the addition of a cGMP workshop at Flamma Honkai and the recent receipt of a cGMP drug manufacturing license from the Chinese FDA. Flamma’s Italian sites also recently added a new cGMP kilo lab as well as a high containment lab to handle genotoxic materials. Flamma intends to invest ~$10M USD to expand its R&D capabilities with the addition of a new R&D building at its Chignolo d’Isola headquarters soon.

To learn more about Flamma, they will be present at numerous upcoming industry events to discuss its plans. The next event will be CPhI Worldwide in Frankfurt in November 2019.

Contact Flamma

Kenneth Drew, Ph.D., Sr. Director, North America Sales and Business Development

1-617-515-0975

04/02/2020

FLAMMA announces the successful CFDA inspection of Flamma Honkai

Chignolo D’Isola, Bergamo, Italy – March 20, 2019 ...

MORE

FLAMMA announces the successful CFDA inspection of Flamma Honkai

06/19/2019

Chignolo D’Isola, Bergamo, Italy – March 20, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that Flamma Honkai has passed its first Chinese FDA (CFDA) inspection that took place in December 2018. Part of the Flamma Group, Flamma Honkai is a 100% owned and managed facility in Dalian, China, that is part of the fully integrated supply chain that Flamma can offer customers.

Flamma Honkai opened its new cGMP workshop in June 2017 to continue to address customer desires for more options when it comes to selecting a CDMO that they can trust especially when working overseas in Asia.

This milestone is part of the Flamma 2020 Plan to bring improvement across its network of manufacturing sites. This certification of the Flamma Honkai facility adds another customer option when working with the Flamma Group.

Dr. Gian Paolo Negrisoli, President and CEO of Flamma noted, “This is a strategic and important milestone for Flamma Honkai and Flamma. The efforts made over the past several years have been exceptional.”

“Flamma has been listening to its customers and their need to have a trusted supplier in China,” said Kenneth Drew, Ph.D., Sr. Director of North America Sales and Business Development. “Flamma is unique in our industry by having the ability to provide customers manufacturing of APIs, RSMs, and advanced intermediates from both Europe and China while being led by one management team. Also, with all the consolidation of the CMO industry, being a family-owned, privately held and managed company still brings significant value to our customers. Having that long-term vision continues to differentiate Flamma from other CMOs and CDMOs.”

The Flamma Honkai site comprises two production workshops, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.

Flamma continues to reinvest in itself for the future. In the next two years, Flamma will increase the amount of investments in its three sites. Compared to Flamma’s 2018 Capital Expenditures (CAPEX) which were $15M USD, Flamma intends to invest $20M USD including $9M USD to expand its R&D capabilities with the addition of a new R&D building at its Chignolo d’Isola headquarters.

To learn more about Flamma, they will be present at numerous upcoming 2019 industry events to discuss its plans. These events include DCAT in New York City in March 2019, CPhI North America in Chicago in April/May 2019 as well as CPhI Worldwide in Frankfurt on November 2019.

Contact Flamma

Kenneth Drew, Ph.D., Sr. Director, North America Sales and Business Development

1-617-515-0975

03/10/2020

FLAMMA Opens New cGMP Kilo Lab Suite in Italy and plans construction of new R&D building

Chignolo D’Isola, Bergamo, Italy – March 20, 2019 ...

MORE

FLAMMA Opens New cGMP Kilo Lab Suite in Italy and plans construction of new R&D building

06/18/2019

Chignolo D’Isola, Bergamo, Italy – March 20, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has completed the construction of its first cGMP Kilo Lab at its Chignolo D’Isola Headquarters in Italy.

The cGMP Kilo Lab is currently being used for an internal Flamma project in conjunction with its Flow Chemistry Pilot Unit. Meanwhile, customers with projects are reserving production slots for later in 2019.

This investment is part of the Flamma 2020 Plan to bring improvement across its network of manufacturing sites. This addition to the Chignolo site adds another option when working with Flamma’s API site.

GianMarco Negrisoli, Corporate Development Manager at Flamma and CEO of Flamma Innovation, remarked: “The opening of a cGMP kilo lab not only increases capabilities of our facility but also allows our customers greater flexibility in working with Flamma. The ability to place projects in Italy or China and knowing that Flamma is actively managing all our sites is comforting to our customer base.”

Flamma will also begin construction of its new R&D building at our headquarters in Chignolo later this year. “This will quadruple our R&D space thus allowing to continue to grow our staff of researchers to serve the pharma industry and the demands of our current customers as well as future customers,” noted Kenneth Drew, Ph.D., Sr. Director North America Sales and Business Development. “The additional benefit of this addition is the ability to have a fully dedicated analytical building for our growing quality team.”

“Flamma continues to differentiate ourselves from others with our transparency and long-term vision with customers. We are proud to be family owned and run since 1950 since we do not have to answer to demands made from shareholders, private equity groups, or venture capital firms” notes Drew.

To learn more about Flamma, they will be present at numerous upcoming 2019 industry events to discuss its plans. These events include DCAT in New York City in March 2019, CPhI North America in Chicago in April/May 2019 as well as CPhI Worldwide in Frankfurt on November 2019.

Contact: Kenneth Drew, Ph.D.,

Sr. Director, North America Sales and Business Development

Tel: 1-617-515-0975

01/29/2020

FLAMMA sweeps 2018 CDMO Leadership Awards for the 3rd year in a row

Chignolo D’Isola, Bergamo, Italy – March 9, 2018 –...

MORE

FLAMMA sweeps 2018 CDMO Leadership Awards for the 3rd year in a row

03/09/2018

Chignolo D’Isola, Bergamo, Italy – March 9, 2018 – Flamma SpA (“Flamma”), a preeminent Contact Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small-molecule active pharmaceutical ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has been once again awarded the maximum number of available CDMO Leadership Awards for 2018.

Flamma was recognized as a Top Performer for the 3rd straight year in all 6 CDMO Core Award Categories: Expertise, Reliability, Capabilities, Quality, Service and Compatibility. Flamma averaged a ranking within the top 3 of the 110 contract manufacturers evaluated.

Flamma was also been recognized as a Top Performer in all 7 Specialty Award Categories for the 3rd straight year. Those specialty categories are: Accessible Senior Management, State-of-the-Art, Innovation, On-Time Delivery, Right the First Time, Strength of Science, and Reputation.

“Flamma has been extremely grateful to be able to work with such a large number of vibrant customers. The entire Flamma team is thankful to be recognized by those who have worked with us and experienced the Flamma difference,” noted Kenneth Drew, Ph.D., Sr. Director North America Sales and Business Development. “Flamma continues to differentiate ourselves from others with our transparency and long term vision with customers. We are proud to be family owned and run since 1950. We do not have to answer to demands made from shareholders, private equity groups, or venture capital firms.”

Dr. Gian Paolo Negrisoli, President and CEO of Flamma remarked, “Flamma has continued to reinvest into ourselves. After the opening of our cGMP workshop at Flamma Honkai, we are also expanding at our Italian sites. We are focusing on containment and the improvement of occupational. We anticipate that later this year we will begin construction of our new R&D building at our headquarters in Chignolo. This will expand our R&D capabilities as well as allow for a dedicated analytical building. We also recently acquired additional land in Dalian that will allow us to build a new state of the art facility at Flamma Honkai.”

Life Science Leader started the CDMO Leadership Awards seven years ago. Industry Standard Research (ISR) conducts the research for Life Science Leader’s CDMO Awards. For the 2018 CDMO Awards data, more than 110 contract manufacturers were evaluated on 23 different performance metrics. Research participants were recruited from pharmaceutical companies of all sizes and were screened for decision-making influence and authority when it comes to working with CDMOs. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data. This validates these awards to be true and legitimate unlike others. This is the only legitimate industry award based on real data from real decision makers.

Flamma will proudly accept its CDMO Leadership Awards on March 21, 2018 at the reception and ceremony held at the W Hotel in New York City.

Contact: Kenneth Drew, Ph.D.,

Sr. Director, North America Sales and Business Development

Tel: 1-617-515-0975